On 20 September 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mylotarg 5 mg powder for solution for infusion, intended for the treatment of acute myeloid leukaemia. The company that applied for authorisation is Wyeth Europa Ltd. The applicant requested a re-examination of the opin ion. After having considered the grounds for this request, the CHMP re-examined the initial opinion , and confirmed the refusal of the marketing authorisation on 24 January 2008.
Questions and answers on the recommendation for the refusal of the marketing authorization for Mylotarg (PDF/35.14 KB)
First published: 24/01/2008
Last updated: 24/01/2008
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Leukemia, Myeloid, Acute
|Anatomical therapeutic chemical (ATC) code||
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.
Wyeth Europa Ltd
|Date of opinion||
|Date of refusal of marketing authorisation||